血脂康胶囊的基础与临床研究进展 - Suppr

Suppr

超能文献

Advance in basic and clinical research of Xuezhikang Capsule.

作者信息

Lu Zong-liang, Xu Zhi-min, Kou Wen-rong, Zhao Shui-ping

机构信息

Fuwai Hospital of Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing 100037, China.

出版信息

Chin J Integr Med. 2006 Jun;12(2):85-93. doi: 10.1007/BF02857352.

DOI:10.1007/BF02857352

PMID:16800985

Abstract

摘要

相似文献

Advance in basic and clinical research of Xuezhikang Capsule.血脂康胶囊的基础与临床研究进展

Chin J Integr Med. 2006 Jun;12(2):85-93. doi: 10.1007/BF02857352.

Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.血脂康对有心肌梗死病史老年患者心血管事件及死亡率的影响：中国冠心病二级预防研究老年受试者的亚组分析

J Am Geriatr Soc. 2007 Jul;55(7):1015-22. doi: 10.1111/j.1532-5415.2007.01230.x.

[Progress of studies on effects of xuezhikang capsule besides lipids regulating].[血脂康胶囊除调节血脂外的作用研究进展]

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Jul;31(7):1000-3.

[China coronary secondary prevention study: analysis of patients with different myocardial infarction history].[中国冠心病二级预防研究：不同心肌梗死病史患者的分析]

Zhonghua Nei Ke Za Zhi. 2006 Jan;45(1):21-4.

Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).血脂康对中国冠心病二级预防研究（CCSPS）中既往有心肌梗死病史的老年高血压患者心血管事件及死亡率的有益影响。

J Clin Pharmacol. 2009 Aug;49(8):947-56. doi: 10.1177/0091270009337509.

[China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes].[中国冠心病二级预防研究（CCSPS）：冠心病合并糖尿病患者的分析结果]

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1067-70.

Anti-inflammatory and antinociceptive effects of Chinese medicine SQ gout capsules and its modulation of pro-inflammatory cytokines focusing on gout arthritis.中药 SQ 痛风胶囊的抗炎和镇痛作用及其对促炎细胞因子的调节作用，针对痛风性关节炎。

J Ethnopharmacol. 2013 Dec 12;150(3):1071-9. doi: 10.1016/j.jep.2013.10.016. Epub 2013 Oct 22.

[China coronary secondary prevention study (CCSPS)].[中国冠心病二级预防研究（CCSPS）]

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Feb;33(2):109-15.

Pharmacodynamic action and mechanism of Du Liang soft capsule, a traditional Chinese medicine capsule, on treating nitroglycerin-induced migraine.中药制剂都梁软胶囊治疗硝酸甘油诱发偏头痛的药效学作用及机制

J Ethnopharmacol. 2017 Jan 4;195:231-237. doi: 10.1016/j.jep.2016.11.025. Epub 2016 Nov 17.

Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS).血脂康，一种红曲提取物，可降低2型糖尿病合并冠心病患者的心血管事件：中国冠心病二级预防研究（CCSPS）中2型糖尿病患者的亚组分析。

J Cardiovasc Pharmacol. 2007 Feb;49(2):81-4. doi: 10.1097/FJC.0b013e31802d3a58.

引用本文的文献

The effect of adropin on lipid and glucose metabolism in rats with hyperlipidemia.内脂素对高脂血症大鼠脂质和葡萄糖代谢的影响。

Iran J Basic Med Sci. 2016 Mar;19(3):245-51.

Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia.红曲米可修复高脂血症大鼠模型的肾损伤并降低炎症转录因子。

Exp Ther Med. 2014 Dec;8(6):1737-1744. doi: 10.3892/etm.2014.2035. Epub 2014 Oct 21.

A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia.血脂康（红曲提取物）治疗冠心病伴血脂异常的系统评价

Evid Based Complement Alternat Med. 2012;2012:636547. doi: 10.1155/2012/636547. Epub 2012 Apr 12.

本文引用的文献

[China coronary secondary prevention study (CCSPS)].[中国冠心病二级预防研究（CCSPS）]

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Feb;33(2):109-15.

Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina.血脂康（红曲提取物）对血脂谱和C反应蛋白的影响：稳定型心绞痛患者的短期病程研究

Clin Chim Acta. 2005 Feb;352(1-2):217-24. doi: 10.1016/j.cccn.2004.09.026.

Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.血脂康，一种红曲提取物，通过抗炎和降脂机制保护冠心病患者的内皮功能。

Circulation. 2004 Aug 24;110(8):915-20. doi: 10.1161/01.CIR.0000139985.81163.CE. Epub 2004 Aug 16.

[Effect of xuezhikang on blood lipids, serum oxidized low density lipoprotein, C-reactive protein and fibrinogen in patients with unstable angina pectoris].血脂康对不稳定型心绞痛患者血脂、血清氧化型低密度脂蛋白、C反应蛋白及纤维蛋白原的影响

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 Oct;23(10):750-2.

Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease.血脂康降低冠心病患者血清脂蛋白（a）和C反应蛋白浓度。

Clin Chem. 2003 Aug;49(8):1347-52. doi: 10.1373/49.8.1347.

Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease.血脂康（一种红曲提取物）对冠心病患者高脂餐后餐后甘油三酯血症的影响。

Atherosclerosis. 2003 Jun;168(2):375-80. doi: 10.1016/s0021-9150(03)00142-4.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.普伐他汀对冠心病及初始胆固醇水平范围广泛的患者心血管事件和死亡的预防作用。

N Engl J Med. 1998 Nov 5;339(19):1349-57. doi: 10.1056/NEJM199811053391902.

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.普伐他汀对胆固醇水平正常的心肌梗死患者冠状动脉事件的影响。胆固醇与再发事件试验研究人员。

N Engl J Med. 1996 Oct 3;335(14):1001-9. doi: 10.1056/NEJM199610033351401.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).4444例冠心病患者降胆固醇随机试验：斯堪的纳维亚辛伐他汀生存研究（4S）

Lancet. 1994 Nov 19;344(8934):1383-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验